Schedule 13G ownership disclosure
CytomX Therapeutics Inc
COMMON STOCK · CUSIP: 23284F105
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- FMR LLC
Shares: 15,396,200.00 · Class: 9.3%
- Abigail P. Johnson
Shares: 15,396,200.00 · Class: 9.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000315066-25-002714
- Form type
- SCHEDULE 13G/A
- Filer
- CytomX Therapeutics, Inc.
- CIK
- CIK 1501989
- Filed
- Nov 05, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership